ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,891.11
1.59%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) Noticias

BBIO BridgeBio Pharma Inc

28.48
0.74 (2.67%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
BridgeBio Pharma Inc BBIO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.74 2.67% 28.48 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
28.45 27.17 28.78 27.83 27.74
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202406:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
02/5/202406:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
10/4/202406:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
07/4/202412:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
20/3/202406:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
06/3/202416:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/3/202416:13EDGAR2Form 8-K - Current report
05/3/202422:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
04/3/202416:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202415:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
04/3/202406:00EDGAR2Form 8-K - Current report
04/3/202401:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
22/2/202415:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202406:31EDGAR2Form 8-K - Current report
22/2/202406:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
21/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:06EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
13/2/202415:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202406:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
06/2/202406:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/2/202406:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
02/2/202406:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
30/1/202406:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
18/1/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202406:30EDGAR2Form 8-K - Current report
18/1/202406:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
16/1/202415:04EDGAR2Form 144 - Report of proposed sale of securities
10/1/202416:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
10/1/202406:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
08/1/202416:14EDGAR2Form 8-K - Current report
05/1/202415:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/1/202415:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
03/1/202406:30GLOBEBridgeBio announces FDA clearance of IND application for..
19/12/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/12/202315:13EDGAR2Form 144 - Report of proposed sale of securities
13/12/202306:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..
08/12/202306:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/12/202307:52DJNBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin..
05/12/202306:44GLOBEBridgeBio Pharma Announces Submission of New Drug..
20/11/202315:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202315:27EDGAR2Form 144 - Report of proposed sale of securities
17/11/202315:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202315:03EDGAR2Form 144 - Report of proposed sale of securities
12/11/202309:30GLOBEBridgeBio Pharma Presents Additional Clinical Outcomes Data..
09/11/202306:30GLOBEBridgeBio Pharma to Present Additional Data from the Phase 3..
08/11/202306:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
02/11/202315:59EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202306:31EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
BBIO
BridgeBio Pharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados